ReviewDevelopment, growth & differentiation2021
Stem-cell-based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies.
Review in Development, growth & differentiation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions.International journal of molecular sciences · 2026Review
- Review
- Stem cell-based therapies for inherited retinal diseases - Translational advances and clinical evidence: A review.Biomolecules & biomedicine · 2026Review
- Monitoring Gene Expression in Retina with synthetic serum markers.bioRxiv : the preprint server for biology · 2026Article
- Subretinal suspensions of hiPSC-derived retinal pigment epithelium cells form functional monolayers in NOD-SCID mice facilitating treatment of advanced retinal diseases.Regenerative therapy · 2025Article
- Applications of Modern Cell Therapies: The Latest Data in Ophthalmology.Life (Basel, Switzerland) · 2025Review
- Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology.International ophthalmology · 2025Review
- Classification of fundus autofluorescence images based on macular function in retinitis pigmentosa using convolutional neural networks.Japanese journal of ophthalmology · 2025Observational
- Tackling visual impairment: emerging avenues in ophthalmology.Frontiers in medicine · 2025Review
- Development of TRIB3-Based Therapy as a Gene-Independent Approach to Treat Retinal Degenerative Disorders.International journal of molecular sciences · 2024Article
- Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024Review
- Relationship between residual visual field and full-field stimulus testing in patients with late-stage retinal degenerative diseases.Scientific reports · 2024Review
- Cell-cell interaction in the pathogenesis of inherited retinal diseases.Frontiers in cell and developmental biology · 2024Review
- Therapeutic Extracellular Vesicles from Tonsil-Derived Mesenchymal Stem Cells for the Treatment of Retinal Degenerative Disease.Tissue engineering and regenerative medicine · 2023Article
- Comprehensive Analysis of Photoreceptor Outer Segments: Flow Cytometry Characterization and Stress-Driven Impact on Retinal Pigment Epithelium Phagocytosis.International journal of molecular sciences · 2023Article
- Bankable human iPSC-derived retinal progenitors represent a valuable source of multipotent cells.Communications biology · 2023Article
- miR-124-3p regulates the proliferation and differentiation of retinal progenitor cells through SEPT10.Cell and tissue research · 2023Article
- Advancements in Ocular Regenerative Therapies.Biology · 2023Review
- Assessing Rewiring of the Retinal Circuitry by Electroretinogram (ERG) After Inner Retinal Lesion in Adult Zebrafish.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various advances have been made in the treatment of retinal diseases, including new treatment strategies and innovations in surgical devices. However, the treatment of degenerative retinal diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), continues to pose a significant challenge. In this review, we focus on the use of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to treat retinal diseases by harnessing the ability of stem cells to differentiate into different body tissues. The retina is a tissue specialized for light sensing, and its degradation leads to vision loss. As part of the central nervous system, the retina has very low regenerative capability, and therefore, treatment options are limited once it degenerates. Nevertheless, innovations in methods to induce the generation of retinal cells and tissues from ESCs/iPSCs enable the development of novel approaches for these irreversible diseases. Here we review some historical background and current clinical trials involving the use of stem-cell-derived retinal pigment epithelial cells for AMD treatment and stem cell-derived retinal cells/tissues for RP therapy. Finally, we discuss our future vision of regenerative treatment for retinal diseases with a partial focus on our studies and introduce other interesting approaches for restoring vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.